bêta
IA Trial Radar
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial 50 Post-partum

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT07449039 (POSTPOD) est une étude interventionnel pour Diabète sucré gestationnel pendant la grossesse. Son statut actuel est : en recrutement. L'étude a débuté le 28 septembre 2025 et vise à recruter 50 participants. Dirigée par l'Université de Californie à Los Angeles, l'étude devrait être terminée d'ici le 1 juin 2030. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 4 mars 2026.
Résumé succinct
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.

Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will al...

Afficher plus
Titre officiel

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

Pathologies
Diabète sucré gestationnel pendant la grossesse
Autres identifiants de l'étude
  • POSTPOD
  • 25-0020
Numéro NCT
NCT07449039
Date de début (réel)
2025-09-28
Dernière mise à jour publiée
2026-03-04
Date de fin (estimée)
2030-06
Inscription (estimée)
50
Type d'étude
Interventionnel
PHASE
N/A
Statut
En recrutement
Objectif principal
Autre
Méthode d'allocation
N/A
Modèle d'intervention
Groupe unique
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
AutreContinuous Glucose Monitor
Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data.
Continuous Glucose Monistor
Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off.
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test
Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT
24 hours postpartum and 1-3 months postpartum
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum
Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c
24 hours postpartum and 1-3 months postpartum
Critère secondaire d'évaluation
Critères d'évaluationDescription de la mesurePériode
Patient satisfaction with CGM use immediately postpartum to evaluate long term risk
Patient satisfaction will be measured via survey response on following statements using 5 point likert scale * Applying the CGM was painless. * Applying the CGM was easy. * Wearing the CGM for 24 hours postpartum was painless. * Wearing the CGM for 24 hours postpartum was easy. * Wearing the CGM did not interfere with my activities of daily living. * Wearing the CGM did not cause any side effects. * Removing the CGM was painless. * Removing the CGM was easy. * If given a choice between the 1-3 month postpartum OGTT and wearing the CGM for 24 hours immediately postpartum, I would choose wearing the CGM.
1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test
Assistant à la participation
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Femme
  • Prenatal care at UCLA Health
  • Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
  • Confirmed gestational diabetes diagnosis based on 2-step approach
  • Maternal age >= 18 years

  • Pre-gestational diabetes (T1DM or T2DM)
  • Multifetal gestation
  • Intra-amniotic infection by clinical criteria
  • Postpartum hemorrhage
  • Maternal ICU admission
  • Known allergy to medical-grade adhesive
  • Presence of skin lesions at anticipated CGM application site
  • Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
  • Metformin use
  • Steroid use
  • Terbutaline use within 4 hours of delivery
  • Cystic fibrosis
  • MODY (mature onset of diabetes in the young)
University of California, Los Angeles logoUniversité de Californie à Los Angeles341 essais cliniques actifs à explorer
Partie responsable de l'étude
Christina S. Han, Investigateur principal, Division Director, Maternal-Fetal Medicine, University of California, Los Angeles
Contact central de l'étude
Contact: Rujuta Sathe, 310-794-8893, [email protected]
Contact: Dana Levin-Lopez, MPH, 310-794-8893, [email protected]
1 Centres de l'étude dans 1 pays

California

University of California, Los Angeles, Los Angeles, California, 90095, United States
Dana Levin-Lopez, MPH, Contact, 310-794-8893, [email protected]
En recrutement